New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis

44Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

Abstract

The male sex has a higher risk to develop coronary artery diseases, including atherosclerosis. The androgen receptor (AR) is expressed in several atherosclerosis-associated cell types, including monocytes/macrophages, endothelial cells (ECs), and smooth muscle cells (SMCs), but its pathophysiological role in each cell type during the development of atherosclerotic lesions remains unclear. Using the Cre-loxP system, we selectively knocked out AR in these 3 cell types and the resultant AR knockout (ARKO) mice, monocyte/macrophage ARKO, EC-ARKO, and SMC-ARKO, were then crossed with the low-density lipoprotein receptor (LDLR) deficient (LDLR-/-) mice to develop monocyte/macrophage ARKO-LDLR-/-, EC-ARKO-LDLR -/-, and SMC-ARKO-LDLR-/- mice for the study of atherosclerosis. The results showed that the monocyte/macrophage ARKO-LDLR -/- mice had reduced atherosclerosis compared with the wild-type-LDLR-/- control mice. However, no significant difference was detected in EC-ARKO-LDLR-/- and SMCARKO-LDLR-/- mice compared with wild-type-LDLR-/- mice, suggesting that the AR in monocytes/macrophages, and not in ECs and SMCs, plays a major role to promote atherosclerosis. Molecular mechanism dissection suggested that AR in monocytes/macrophages upregulated the tumor necrosis factor-α, integrin β2, and lectin-type oxidized LDL receptor 1 molecules that are involved in 3 major inflammation-related processes in atherosclerosis, including monocytes/macrophages migration and adhesion to human umbilical vein ECs, and subsequent foam cell formation. Targeting AR via the AR degradation enhancer, ASC-J9, in wild-type-LDLR-/- mice showed similar effects as seen in monocyte/macrophage ARKO-LDLR-/- mice with little influence on lipid profile. In conclusion, the AR in monocytes/macrophages plays key roles in atherosclerosis and targeting AR with ASC-J9 may represent a new potential therapeutic approach to battle atherosclerosis. © 2014 American Heart Association, Inc.

Cite

CITATION STYLE

APA

Huang, C. K., Pang, H., Wang, L., Niu, Y., Luo, J., Chang, E., … Chang, C. (2014). New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis. Hypertension, 63(6), 1345–1353. https://doi.org/10.1161/HYPERTENSIONAHA.113.02804

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free